Agree To Buy Regeneron Pharmaceuticals At $195, Earn 8.9%

Investors considering a purchase of Regeneron Pharmaceuticals ( REGN) stock, but cautious about paying the going market price of $293.78/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $195 strike, which has a bid at the time of this writing of $17.30. Collecting that bid as the premium represents a 8.9% return against the $195 commitment, or a 6.7% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

Top YieldBoost Puts of the Nasdaq 100 »

Selling a put does not give an investor access to REGN's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $195 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless Regeneron Pharmaceuticals, Inc. sees its shares fall 33.3% and the contract is exercised (resulting in a cost basis of $177.70 per share before broker commissions, subtracting the $17.30 from $195), the only upside to the put seller is from collecting that premium for the 6.7% annualized rate of return.

Below is a chart showing the trailing twelve month trading history for Regeneron Pharmaceuticals, Inc., and highlighting in green where the $195 strike is located relative to that history:

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round